Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial
Michael K. Lim, Xiaobu Ye, Anna F. Piotrowski, ARATI DESAI et autres
Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint implicated in T cell exhaustion and a potential therapeutic target in glioblastoma (GBM). We conducted a multicenter, open-label, phase 1 study with sequential allocation to evaluate the safety and preliminary activity of the …
us (code pays fourni par la source)
0 citations
Nature Medicine